SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-020454
Filing Date
2024-05-06
Accepted
2024-05-06 07:03:14
Documents
14
Period of Report
2024-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20240506.htm   iXBRL 8-K 33359
2 EX-99.1 ex991earningspressrelease5.htm EX-99.1 81010
  Complete submission text file 0001628280-24-020454.txt   253579

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20240506.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20240506_lab.xml EX-101.LAB 22543
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20240506_pre.xml EX-101.PRE 13047
17 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20240506_htm.xml XML 2829
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 24915509
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)